# Study of YK012 in Primary Membranous Nephropathy

> **NCT06982729** · PHASE1 · RECRUITING · sponsor: **Excyte Biopharma Ltd** · enrollment: 72 (estimated)

## Conditions studied

- Primary Membranous Nephropathy

## Interventions

- **DRUG:** YK012

## Key facts

- **NCT ID:** NCT06982729
- **Lead sponsor:** Excyte Biopharma Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-08
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06982729

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06982729, "Study of YK012 in Primary Membranous Nephropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06982729. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*